Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

18.06 0.95

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.85

Max

18.29

Põhinäitajad

By Trading Economics

Sissetulek

-607K

-51M

Müük

-28M

100M

Aktsiakasum

-0.46

Kasumimarginaal

-51.215

Töötajad

1,784

EBITDA

4.1M

-44M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+68.6% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-279M

2.1B

Eelmine avamishind

17.11

Eelmine sulgemishind

18.06

Uudiste sentiment

By Acuity

100%

0%

322 / 340 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. juuli 2026, 23:56 UTC

News

Old Dominion Freight Line shares lower in after-market hours after UBS raised its price target to $228 while maintaining a Neutral rating.

30. juuli 2026, 23:56 UTC

News

DICK'S Sporting Goods Inc. sees gains in after-market trading, supported by solid fundamentals and recognition as a value stock despite mixed performance momentum.

30. juuli 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

30. juuli 2026, 23:56 UTC

News

Check Point Software Technologies reported earnings of $2.55 per share, surpassing expectations of $2.45. Shares are little changed in after-market trading.

30. juuli 2026, 23:52 UTC

News
Social Media

Amazon.com Inc shares rose in after-hours trading following strong second-quarter results, with net sales of $200.6 billion surpassing analyst expectations.

30. juuli 2026, 23:51 UTC

News

Kimberly-Clark announced a $10 million commitment for recovery efforts in Wisconsin's Fox Valley, moving higher in after-market hours amid broader market gains.

30. juuli 2026, 23:51 UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

30. juuli 2026, 23:51 UTC

News

Castle Biosciences reported second-quarter revenues of $103.5 million, exceeding estimates. Shares are sharply higher in after-market trading following the earnings and guidance update.

30. juuli 2026, 23:51 UTC

News

Hercules Capital reported second-quarter earnings of $0.50 per share, exceeding estimates. Shares are higher in after-market trading following the strong results.

30. juuli 2026, 23:51 UTC

Correlated Moves
News

EMCOR Group Inc. reported record second-quarter results, with revenue of $5.15 billion and EPS of $9.06, raising full-year guidance. Shares are higher in after-market hours.

30. juuli 2026, 23:51 UTC

Social Media
Correlated Moves
News

Lam Research Corp shares rose in after-market hours following strong second-quarter results, with adjusted EPS of $1.82 and optimistic third-quarter revenue guidance of $8.1 billion.

30. juuli 2026, 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

30. juuli 2026, 23:51 UTC

News
Social Media

Roblox Corp shares fell in after-hours trading following a narrower net loss of $183 million but disappointing revenue and guidance for third-quarter bookings.

30. juuli 2026, 23:51 UTC

News
Social Media

Replimune Group shares are advancing in after-market trading following a favorable FDA advisory vote on its melanoma treatment RP1, despite earlier declines during the session.

30. juuli 2026, 23:51 UTC

News
Event
Social Media

Apple Inc reported fiscal Q3 revenue of $109.4 billion, but shares fell in after-hours trading due to weaker-than-expected guidance and missed services revenue.

30. juuli 2026, 23:46 UTC

News

TFS Financial Corp reported third-quarter EPS of $0.11, surpassing estimates. Shares are higher in after-market trading following strong earnings and revenue results.

30. juuli 2026, 23:46 UTC

News

Eastman Chemical Co reported second-quarter net earnings of $183 million, up from $140 million last year, with shares trading roughly flat in after-market hours.

30. juuli 2026, 23:46 UTC

Correlated Moves
News

UBS raised its price target on Xylem Inc. to $135, as shares traded higher in after-market hours following a dip earlier in the session.

30. juuli 2026, 23:46 UTC

Social Media
News

Yum Brands reported a cyclospora outbreak linked to Taco Bell affecting sales. Shares are trading higher in after-market hours, continuing recent upward momentum.

30. juuli 2026, 23:46 UTC

News

Shares of Netflix are lower in after-market trading following Anne Sweeney's resignation from the board, confirmed not to be due to any disagreement.

30. juuli 2026, 23:41 UTC

News

CareDx Inc reported second-quarter revenue of $132 million, exceeding estimates. Following strong results and raised guidance, shares are higher in after-market trading.

30. juuli 2026, 23:41 UTC

Social Media
Event
News

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

30. juuli 2026, 23:41 UTC

Social Media
Correlated Moves
News

MicroStrategy reported a second-quarter loss of $8.62 billion, significantly missing expectations. Shares are trading higher in after-market hours amid broader market gains.

30. juuli 2026, 23:41 UTC

News
Social Media

Illumina Inc shares declined in after-market trading despite strong second-quarter results and raised full-year EPS guidance, reflecting concerns over falling net income.

30. juuli 2026, 23:41 UTC

Social Media
News

Stryker Corp shares fell in after-market trading despite reporting adjusted EPS of $3.69 and raising full-year guidance to $14.95 to $15.10.

30. juuli 2026, 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

30. juuli 2026, 23:41 UTC

News

Cognizant Technology Solutions shares are lower in after-market trading despite stable revenue and increased profit guidance in its recent second-quarter update.

30. juuli 2026, 23:41 UTC

Correlated Moves
News
Social Media

Micron Technology's after-market hours trading rises significantly, driven by a broader market rally and a $153 billion increase in market capitalization.

30. juuli 2026, 23:41 UTC

News

Bloom Energy Corp shares are higher in after-market hours, driven by strong performance in the Heavy Electrical Equipment sector and significant revenue growth.

30. juuli 2026, 23:41 UTC

News

PTC Inc. gained in after-market hours, driven by strong quarterly results and raised revenue guidance, reaching a high of 2.82% since Thursday's close.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

68.6% tõus

12 kuu keskmine prognoos

Keskmine 30.87 USD  68.6%

Kõrge 44 USD

Madal 21.6 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

322 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat